Prot #BMT CTN 1506/2215-CL-0304: A Multi-Center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML

Project: Research project

Project Details

StatusFinished
Effective start/end date4/12/18 → 4/12/21

Funding

  • National Marrow Donor Program (Prot #BMT CTN 1506/2215-CL-0304)
  • Astellas Pharma Global Development, Inc. (Prot #BMT CTN 1506/2215-CL-0304)
View all
View less